ESR1 and breast cancer: In the NA‐PHER2 study, the tpCR rate was 27% following neoadjuvant trastuzumab and pertuzumab plus palbociclib, and fulvestrant in patients with ER‐positive, HER2‐positive early or locally advanced breast cancer.22